Kisspeptin

Endogenous hypothalamic neuropeptide family (Kisspeptin-54 and shorter fragments) acting via KISS1R to gate GnRH, LH/FSH secretion and human fertility.

Evidence: Robust Human & Preclinical Function: Reproductive Axis / IVF Class: GnRH upstream neuromodulator

Clinical focus & potential applications

Kisspeptin (encoded by KISS1) is now recognized as a master regulator of the hypothalamic–pituitary–gonadal (HPG) axis, providing excitatory drive to GnRH neurons and thereby controlling LH/FSH secretion, pubertal onset and fertility. Loss-of-function mutations in KISS1 or its receptor KISS1R (GPR54) cause hypogonadotropic hypogonadism and infertility, while exogenous kisspeptin administration acutely stimulates GnRH/LH in both healthy individuals and patients with reproductive disorders. Clinically, kisspeptin-54 has been evaluated as a safer ovulation trigger in IVF and is under investigation for hypothalamic amenorrhoea and other infertility contexts.

Clinical research areas

How kisspeptin is being translated from neuroendocrine discovery into fertility-focused interventions.

Infertility and hypogonadotropic hypogonadism: diagnostic and therapeutic exploration in patients with hypothalamic GnRH deficiency or functional hypothalamic amenorrhoea.
IVF ovulation triggering: kisspeptin-54 used as an alternative to hCG or GnRH agonists to induce oocyte maturation while aiming to reduce ovarian hyperstimulation syndrome (OHSS) risk.
Pubertal disorders: mechanistic work and early case data in delayed puberty and central hypogonadism due to disrupted KISS1/KISS1R signaling.
HPG-axis mapping: use of kisspeptin infusion tests to probe GnRH neuron integrity and pituitary responsiveness in complex reproductive endocrine disorders.
Potential future roles in polycystic ovary syndrome (PCOS), obesity-related infertility and male factor infertility via modulation of GnRH/LH pulse patterns.

Mechanism stack

Key neuroendocrine mechanisms that make kisspeptin a master regulator of human reproduction.

Core pathway

KISS1 → KISS1R on GnRH neurons

Kisspeptins, primarily kisspeptin-54 and shorter fragments, are produced by KISS1 neurons in the hypothalamus. They bind KISS1R (GPR54) expressed on GnRH neurons, causing strong depolarization and GnRH release, which in turn drives pituitary LH and FSH secretion.

Pulse generator

KNDy network & GnRH pulsatility

In the arcuate nucleus, kisspeptin neurons co-express neurokinin B (NKB) and dynorphin (the “KNDy” network), which together set the timing of GnRH pulses. This pulsatile pattern is crucial for normal pubertal development, ovarian cycles and spermatogenesis.

Sex-steroid feedback

Estrogen-dependent positive & negative feedback

Distinct kisspeptin neuron populations in the arcuate nucleus and anteroventral periventricular area integrate estrogen and progesterone feedback, mediating both negative feedback during most of the cycle and the pre-ovulatory positive feedback that generates the LH surge.

Clinical pharmacology

Exogenous kisspeptin-54 effects

Intravenous or subcutaneous kisspeptin-54 in humans acutely increases LH and often FSH, with responses depending on sex, cycle phase and underlying pathology, providing a pharmacologic tool to transiently “push” the GnRH–LH/FSH axis.

Evidence snapshot

Representative findings from genetic, mechanistic and clinical kisspeptin studies.

Model / context	Observation	Notes
KISS1 / KISS1R loss-of-function in humans Genetic evidence	Inactivating mutations in KISS1 or KISS1R cause normosmic congenital hypogonadotropic hypogonadism with absent or severely delayed puberty and infertility, demonstrating that kisspeptin signaling is essential for human reproductive axis activation.	Strong causal link between kisspeptin signaling and fertility, not just correlation.
Kisspeptin excitation of GnRH neurons (rodent & primate) Neurophysiology	Kisspeptin directly depolarizes GnRH neurons, increases firing rate and evokes GnRH release in hypothalamic slice and in vivo preparations, confirming a primary role as an upstream excitatory input to the GnRH network.	Provides the mechanistic basis for kisspeptin’s strong LH/FSH effects in vivo.
Acute kisspeptin-54 administration in adults Human endocrine tests	Intravenous or subcutaneous kisspeptin-54 boluses increase LH (and to a lesser extent FSH) in healthy men and women, as well as in some patients with hypothalamic hypogonadism, with responses modulated by sex-steroid milieu.	Confirms pharmacologic activatability of GnRH neurons in many clinical contexts.
IVF ovulation trigger trials Clinical IVF	In women undergoing IVF, a single kisspeptin-54 injection given at the end of ovarian stimulation successfully triggered oocyte maturation, producing viable oocytes, fertilization, embryo transfer and live births, with a favorable ovarian hyperstimulation syndrome profile in early studies.	Positions kisspeptin as a potential alternative to hCG or GnRH agonists for oocyte maturation, especially in high-risk OHSS patients.
Functional hypothalamic amenorrhoea (FHA) & other hypogonadism Emerging clinical uses	Pilot studies show that repeated kisspeptin administration can elicit LH pulses and, in some women with FHA, partial restoration of HPG-axis activity, though tachyphylaxis and variable responses limit straightforward chronic use.	Suggests a role as a diagnostic or intermittent therapeutic tool rather than continuous replacement therapy.

Risk frame & unknowns

Practical limitations and open questions for kisspeptin-based therapies.

Important clinical caveats

Most clinical data come from small, single- or few-center studies; large Phase III trials are still needed before routine use as a fertility drug or IVF trigger.
Repeated or continuous kisspeptin exposure can lead to desensitization (tachyphylaxis) of the GnRH–LH axis, complicating long-term dosing strategies.
Optimal dosing, timing and patient selection (e.g. type of hypogonadism, BMI, sex-steroid status) remain areas of active research.
Because kisspeptin acts upstream of GnRH, any underlying pituitary or gonadal pathology may blunt or alter responses, requiring careful endocrine evaluation before therapeutic use.

This dossier summarizes mechanistic, preclinical and clinical findings on kisspeptin for scientific and educational purposes only. It does not provide medical advice, treatment guidance or dosing recommendations.